Compare Globus Medical Inc. Class A Common Stock (GMED) vs Philip Morris International Inc. (PM) Price & Performance

Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.

GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.

Philip Morris International (PM) trades at $202.00, up 0.4% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $212.17. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.20, and maintains robust profitability with a net income margin of 25.56%. Recent news highlights growth in smoke-free products like IQOS and ZYN, now over 40% of revenue, and a raised 2026 EPS forecast due to favorable currency impacts.

The stock offers a compelling growth story driven by smoke-free product expansion and dividend reliability, but faces risks from regulatory pressures and high valuation multiples. With 68% of analysts rating it a Buy, upside exists toward the $225 high target, though investors should monitor debt levels and industry shifts.